Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty
This article was originally published in The Pink Sheet Daily
Executive Summary
Story outside: Trials in other indications can suffice as confirmatory trials for accelerated approval in the relapsed/refractory settings, FDA says during advisory committee review